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Background: Mutations in the gene encoding for dysferlin cause recessive autosomal muscular dystrophies called
dysferlinopathies. These mutations induce several alterations in skeletal muscles, including, inflammation, increased
membrane permeability and cell death. Despite the fact that the etiology of dysferlinopathies is known, the
mechanism that explains the aforementioned alterations is still elusive. Therefore, we have now evaluated the
potential involvement of connexin based hemichannels in the pathophysiology of dysferlinopathies.
Results: Human deltoid muscle biopsies of 5 Chilean dysferlinopathy patients exhibited the presence of muscular
connexins (Cx40.1, Cx43 and Cx45). The presence of these connexins was also observed in human myotubes
derived from immortalized myoblasts derived from other patients with mutated forms of dysferlin. In addition to
the aforementioned connexins, these myotubes expressed functional connexin based hemichannels, evaluated by
ethidium uptake assays, as opposed to myotubes obtained from a normal human muscle cell line, RCMH. This
response was reproduced in a knock-down model of dysferlin, by treating RCMH cell line with small hairpin RNA
specific for dysferlin (RCMH-sh Dysferlin). Also, the presence of P2X7 receptor and the transient receptor potential
channel, TRPV2, another Ca2+ permeable channels, was detected in the myotubes expressing mutated dysferlin, and
an elevated resting intracellular Ca2+ level was found in the latter myotubes, which was in turn reduced to control
levels in the presence of the molecule D4, a selective Cx HCs inhibitor.
Conclusions: The data suggests that dysferlin deficiency, caused by mutation or downregulation of dysferlin,
promotes the expression of Cx HCs. Then, the de novo expression Cx HC causes a dysregulation of intracellular free
Ca2+ levels, which could underlie muscular damage associated to dysferlin mutations. This mechanism could
constitute a potential therapeutical target in dysferlinopathies.
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Dysferlinopathies are muscular dystrophies caused by
mutations in dysferlin, a 230 kDa membrane protein,
mainly localized in the sarcolemma [1] and the T-tubule
system [2, 3]. It is accepted that dysferlin participates in
membrane resealing after damage [4, 5]. This protein is
weakly expressed in myoblasts (myogenic precursor
cells), but highly expressed in adult skeletal muscle [6].
Clinically, dysferlinopathies manifest between the second
and third decade of life in previously asymptomatic pa-
tients. At onset, most patients refer weakness in the
lower extremities, difficulty in running or climbing
stairs, sometimes accompanied with pain [7]. Regarding
the alterations produced by dysferlin mutations in
muscle, prior reports have detected the presence of in-
flammation [8–10]; disruption of the T-tubule structure,
which in turn was ameliorated by reduction of external
[Ca2+] or blocking of L-type Ca2+ channels with diltia-
zem [3], suggesting that a deregulated entry of external
Ca2+ may underlie damage in dysferlin null myofibers.
In addition, an altered permeability to dyes such as Ev-
ans blue has been reported in skeletal muscles from
Dysf-/- mice (an animal model of dysferlinopathy) [4],
and previous reports have demonstrated that Evans blue
crosses the cell membrane through Cx HC [11]. Hence,
these results strongly suggest the presence of connexin
based hemichannels (Cx HC) in the sarcolemma of myo-
fibers from the animal model. As we previously reported,
the de novo expression of Cx HCs has been observed in
similar pathologies, where they mediate myofiber atro-
phy induced by denervation [11]. Interestingly, only a
mild muscular atrophy was observed after denervation
in Cx43 and Cx45 KO mice [11]. Since Cx HC are non-
selective channels permeable to ions (e.g. Ca2+ and Na+)
and small compounds, including signaling molecules
such as ATP and NAD+ and dyes including ethidium
(Etd+) and Evans blue [12, 13], the altered membrane
permeability caused by the Cx HC expression could
contribute to the development of the muscular atrophy.
Indeed, the de novo expression of Cx HCs promotes the
increase of oxidative stress in pathological conditions
such as muscle denervation [14] and they constitute a
mechanism of ATP release in several muscle pathologies
[11, 12, 14].
To date there is no effective treatment to arrest or even
reduce the symptomatology of the patients affected with
dysferlinopathies. Nevertheless, the introduction of a
mini-dysferlin in animal models of the disease (Dysf-/-
mice) results in the recovery of membrane resealing func-
tion. However, the progressive degeneration, ascertained
from muscle histology studies, remains unabated [15].
The aforementioned evidence points to the existence of
an additional pathological mechanism, triggered by the
absence of dysferlin. In the present work we evaluatedwhether myotubes of patients suffering from dysferlinopa-
thies, as well as in other in vitro models of dysferlin defi-
ciency, express Cx HCs and whether the expression of
these types of channels alters the sarcolemma permeabil-
ity, and increases intracellular free Ca2+ in these cells.
Results
Human muscles bearing dysferlin mutations express
connexins 40.1, 43 and 45
We analyzed the presence of connexin proteins by
immnunofluorescent microscopy in human muscles
biopsies from patients bearing dysferlin mutations (see
methods for dysferlin mutations), the absence of dysfer-
lin was confirmed by immunohistochemistry assays (data
not shown). As shown in Fig. 1, connexins 40.1, 43 and
45 (green signal, Fig. 1) were detected in biopsies from
patients with dysferlinopathy but not in biopsies of con-
trol subjects (control). These proteins colocalized with
the plasma membrane protein spectrin (Fig. 2) [16], indi-
cating that all three connexins are present in the sarco-
lemma. Using immunofluoresence, we next evaluated
the presence of the purinergic receptor P2X7 and the
transient receptor potential cation channel subfamily V
member 2 (TRPV2), which have been previously associ-
ated with muscular atrophy [11]. P2X7 receptors were
detected in one of the two patients evaluated, whereas
TRPV2 was found in the biopsies of both patients
(Fig. 3). Conversely, in control patients (patients without
a muscular pathology) both receptors were absent
(Fig. 3).
Because Ca2+ influx is reportedly increased in human
muscles bearing dysferlin mutations [17], we evaluated
the presence, in human dysferlin-mutated myotubes
(HDMM) (using immunofluorescent miscroscopy), of
different Ca2+ channels; connexin-based hemichannels,
transient potential receptor TRPV2 and P2X7, all of
which have been previously linked in muscular patholo-
gies [11, 12, 18]. We observed the presence of Cxs 40.1,
43 and 45 in all HDMM, although they have different
dysferlin mutations (Fig. 4, green signal), they were ab-
sent in normal myotubes (Control, RCMH cells). On the
other hand, TRPV2 channels and P2X7 receptors were
only present in 107 and 379 (dysferlin-mutated cell lines,
see methods) derived myotubes (Fig. 4). TRPV2 channels
were functional in 379 myotubes, as evidenced by their
response to stimulation with 2-aminoethoxydiphenyl
borate (2-APB), a selective TRPV2 agonist [19], which
induces a sustained increase in Ca2+ levels (Additional
file 1: Figure S1).
Absence of dysferlin in control RCMH myotubes mimics
the dysferlin mutation effect
To demonstrate that the absence of dysferlin, regardless
of the type of mutation, can induce the expression of
Fig. 2 Connexins 40.1, 43 and 45 are distributed in sarcolemma of human muscles biopsies from dysferlinopathy patients. Connexins 40.1, 43 and
45 (green signal) and the sarcolemma protein spectrin (red signal) were detected by immunofluorescence assay using specific antibodies in
muscular biopsies obtained from a dysferlinopathy patient (dysf 25). Co-localization of a connexin with spectrin is denoted by the yellow signals.
Nuclei were stained with DAPI (blue signal). Scale bar: 50 μm
Fig. 1 Connexins 40.1, 43 and 45 are present in human biopsies from dysferlinopathy patients. Connexin 40.1, 43 and 45 were detected by
immunofluorescence assay using specific antibodies in muscular biopsies obtained from five dysferlinopathy patients at the University of Chile
Clinical Hospital, and from a patient that not bear a muscular pathology (control). Cell nuclei were stained with DAPI (blue signal). Scale
bar: 50 μm
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Fig. 3 Presence of P2X7 receptor and TRPV2 channel in muscular biopsies from dysferlinopathy patients. The purinergic receptor P2X7 and the
transient receptor potential vanilloid type 2 (TRPV2) channel were detected by immunofluorescence studies using specific antibodies in cross
sections of human muscular biopsies from two dysferlinopathy patients and a control patient (patient without a muscular pathology). Nuclei
were stained with DAPI (blue signal). Scale bar: 50 μm
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down expression of dysferlin in RCMH cells by
transfecting a small hairpin RNA specific for dysferlin,
and transfected cells were subsequently differentiated
to myotubes (RCMH-sh Dysf ). In the absence of
dysferlin, RCMH cells express connexins 40.1, 43
and 45 (green signal), which were in control myo-
tubes (RCMH) that express dysferlin (red signal,
Fig. 5).
Human dysferlin-mutated myotubes express functional
connexin based hemichannels
Because Cx proteins are present in dysferlin-mutated
myotubes (Fig. 4), we analyzed whether these proteins
were indeed forming functional hemichannels (Cx HCs)
in these cells. Hemichannel activity was evaluated by
ethidium (Etd+) uptake assays [20], which revealed that
HDMM demonstrated elevated Etd+ uptake compared
with control myotubes (Fig. 6). We detected a 4-fold in-
crement in the 107 and 379 cell lines, compared with
RCMH, whereas AB320 and ER (human dysferlin-
mutated cell lines, see methods) showed an increment of
2-fold compared to RCMH. Etd+ uptake was successfully
inhibited with external application of 50 μM carbenoxolone
(Fig. 5a), a Cx HC inhibitor [21]. In addition, we observed
that different dysferlin mutations exhibit different Cx HC
activity. Indeed, cell lines 107 and 379 presented the high-
est Cx HC activity (Fig. 6b). In addition, RCMH myotubes
where dysferlin was silenced via specific small hairpin RNA
resulted in the expression of functional Cx HCs to levels
comparable to 107 and 379 myotubes (Fig. 6b).Inhibition of connexin-based hemichannels reduces
elevated intracellular basal Ca2+ signals
Considering that Ca2+ influx is reportedly increased in
human muscles bearing dysferlin mutations [17], and
that human dysferlin-mutated myotubes express func-
tional Cx HCs (Fig. 6), which in turn are non-selective
permeable Ca2+channels [22], we analyzed basal cyto-
solic Ca2+ levels in the dysferlin-deficient and control
lines using FURA 2-AM assays. Dysferlin-mutated myo-
tubes showed significantly elevated Ca2+ levels compared
to control myotubes (Fig. 7), a finding consistent with
the increased Cx HC activity observed in the four cell
lines evaluated herein. Since Cx HCs were present and
the basal intracellular Ca2+ level was elevated in dysfer-
lin-mutated myotubes, we then investigated whether the
inhibition of Cx HCs could prevent this phenomenon.
Therefore, human dysferlin-mutated myotubes were
treated daily for 7 days with 100 nM D4, a selective Cx
HC blocker that does not inhibit gap junction channels,
thus allowing the fusion of myoblasts to form myotubes
where gap junction channels are relevant [23]. Incuba-
tion with D4 significantly reverted the intracellular basal
Ca2+ signals to values comparable to those of control
cells (Fig. 7), suggesting that these channels are respon-
sible of this response.
Discussion
In the present report, we have demonstrated that
muscles from patients diagnosed with dysferlinopathy
express Cxs 40.1, 43 and 45 at the plasma membrane.
Additionally, four immortalized muscle cell lines
Fig. 4 Human dysferlin-mutated myotubes present connexins 40.1, 43 and 45. Human dysferlin-mutated myotubes were obtained by
differentiation of dysferlin-mutated myoblast lines named 107, 379, AB320 and ER, each one bearing different dysferlin mutations. Connexins 40.1,
43 and 45 were detected by immunofluorescence studies using specific antibodies. All cell lines showed positive reactivity to Cxs (green signal)
compared with control myotubes (RCMH), where Cxs reactivity was not detected. P2X7 receptor and TRPV2 channel were also detected by
immunofluorescence studies using specific antibodies. Only 107 and 379 myotubes expressed P2X7 receptors and TRPV2 channels. Nuclei were
stained with DAPI (blue signal). Scale bar: 30 μm. n = 4 cell cultures for each cell line
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patients also expressed these Cxs, which in turn,
formed functional Cx-based hemichannels. This
phenomenon was also induced in control myotubes
(RCMH, which normally do not express Cxs), after
decreasing dysferlin expression through the transfec-
tion (in myoblast stage) of a specific small hairpin
RNA against dysferlin. Moreover, human dysferlin-
mutated 107 and 379 myotubes expressed two addi-
tionals Ca2+ permeable channels, the TRPV2 channel
and P2X7 receptor. These myotubes also exhibited
greater Cx HC activity, and such an elevated Cx HCactivity could explain the presence of these channels
in the myotubes, which in turn could also contribute
to the elevated intracellular Ca2+ signal previously
reported in dysferlin KO skeletal muscle fibers [3]
and confirmed here in our model. Anyway, it seems
that the presence of Cx HCs is sufficient to explain
the elevated basal intracellular Ca2+ levels in dysferlin-
deficient myocytes, especially if we consider that the
specific inhibition of these channels with a selective
blocker (molecule D4), was enough to reduce the
elevated basal Ca2+ concentration to levels similar to
those of control cells. The mechanisms regulating Ca2+ in
Fig. 6 Absence of dysferlin promotes elevated connexin-based hemichannel activity in human myotubes. Human dysferlin-mutated myotubes
and control myotubes transfected with small hairpin RNA against Dysferlin (R-sh dysf) were used to evaluate connexin hemichannel activity using
the ethidium (Etd+) uptake assay. Briefly, a Representative curve of Etd+ uptake in myotubes differentiated from 107 myoblast cell line. Notice the
enhanced uptake after incubation in a divalent cation free solution (DCFS), condition that induces opening of Cx HCs. The signals were inhibited
by 50 μM carbenoxolone, a Cx HC blocker. b Graph showing the fold variation between the DCFS-induced slope versus basal slope (Fold of
basal). * P < 0.05; **P < 0.01; ***P < 0.001. n = 4 cell cultures for each cell line
Fig. 5 Silencing of dysferlin induces the presence of connexin 40.1, 43 and 45 in human myotubes. Control RCMH myoblasts were transfected
with small hairpin RNA to decrease dysferlin expression, to be later differentiated to myotubes by culturing in differentiation medium for 14 days.
Once myotubes were obtained, the presence of connexin 40.1, 43, 45 (green signal) and dysferlin (red signal) was analyzed by immunofluorescence
assay using specific antibodies and compared with that of control RCMH myotubes (without transfection). The three connexins, but not dysferlin, were
detected in RCMH-sh Dysferlin myotubes, whereas control RCMH myotubes present dysferlin (red signal) but not Cxs. The nuclei were stained with
DAPI (blue signal). Scale bar: 50 μm. n = 4 cell cultures for each cell line
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Fig. 7 Elevated intracellular basal Ca2+ signal in dysferlin-mutated
myotubes is reduced by Cx HC inhibitor. Four different dysferlin-
mutated myotubes (called 107, 379, AB320 and ER) were used, which
were differentiated to myotubes with differentiation medium (DMEM/
F12 supplemented with 5 % horse serum plus insulin 10 ug/ml). The
Ca2+ signal was evaluated using the FURA-2 AM dye in a fluorescence
microscope. Signals were compared to those obtained in control
myotubes (RCMH). Molecule D4 (D4, 100 nM), a selective connexin
hemichannels (Cx HC) inhibitor, was used. During the last 7 days (D4
was added daily during 7 days) before the Ca2+ measurement was
performed, D4 was applied to prevent the increase of intracellular basal
Ca2+ signal in human dysferlin mutated myotubes. The data represent
as mean ± SEM. ANOVA test with Dunn post test. *P < 0.05. n = 4 cell
cultures for each cell line
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proteins and most importantly the sarcoplasmic/endoplas-
mic reticulum Ca2+ ATPases (SERCA), are extremely effi-
cient in controlling the cytosolic levels of this cation [24].
Even so, integration of Cx hemichannels into the plasma
membrane increased the basal Ca2+ concentration by ~8 %,
which may be enough to alter cellular homeostasis of myo-
cytes. This increment in Ca2+ levels could be enough to
alter the cellular homeostasis of the myocytes. Indeed, an
altered cytosolic Ca2+ level could induce several changes in
the myotubes, including an increased proteolytic activity
[25], which occurs in muscles from patients bearing dysfer-
lin mutations [26]. The latter could then drive atrophy in
affected muscles, and also to cause the degeneration of
muscles by apoptosis or necrosis [18]. These findings have
been previously observed in Duchenne muscular dystrophy
were resting Ca2+ levels in human DMD myotubes were
increased compared with normal myotubes [27].
Therefore, in addition to the deficit in membrane repair
mechanism found in dysferlin-mutated myofibers [4], we
propose herein a second pathological mechanism as a
consequence of dysferlin mutations, which involves Cx
HCs. These non-selective channels could explain several
of the reported features in dysferlin-deficient muscles, in-
cluding the increased membrane permeability [4], higher
proteasome activity [26, 28], activation of inflammation
signals [8–10] and muscle degeneration [29]. The latter
interpretation is supported by prior reports showing therole of Cx HC in altered membrane permeability and atro-
phy of skeletal muscles induced by denervation [11, 12].
Although the mechanism responsible of the induction of
connexins by the absence of dysferlin still remains to be
elucidated, the fact that the knock-down of dysferlin in-
duces the de novo expression of functional connexin-
based hemichannels suggests a direct relation between the
absence of dysferlin and the presence of connexin. How-
ever, it has been demonstrated that some conditions such
as inflammation induces the expression of functional
connexin-based hemichannels in skeletal muscles through
proinflammatory cytokines and the transcription factor
NFκB [11, 12]. Inflammation has been described as a key
feature in dysferlin-mutated skeletal muscles [9]. Whether
the induction of Cx HC involves an activation of NFκB
still needs to be investigated.
Conclusions
In this study, we have demonstrated the presence of
connexins 40.1, 43 and 45 in muscular biopsies of pa-
tients with different dysferlin mutations. This was con-
firmed in myotubes derived from cell lines of human
dysferlinopathy patients, as well as in normal myotubes
where dysferlin was knocked down. The Cxs expressed
formed functional connexin based hemichannels, that
are responsible of elevated basal intracellular Ca2+ levels
in human myotubes. The presence of these channels
may represent a novel pathological mechanism in dysfer-
linopathies, as well as a most attractive therapeutical tar-
get, considering their localization at the membrane level.
Methods
Reagents
Anti-rabbit or anti-mouse IgG antibodies-conjugated to
Cy2 (green) or Cy3 (red) were purchased from Jackson
immunoresearch laboratories (West Grove, PA, USA).
Ethidium (Etd+) bromide was from GIBCO/BRL (Grand
Island, NY, USA), fluoromount-G was from Electron
Microscopy Science (Hatfield, PA, USA), Previously
described polyclonal anti-Cx40.1, -43, and -Cx45 anti-
bodies were used [11]. Synthesis and characterization
of D4 molecule will be published elsewhere.
Generation of dysferlin-mutated myoblast cell lines
The protocol used was obtained from Philippi et al. [30].
Briefly, primary myoblasts isolated by protease digestion
were obtained from fresh muscle biopsies and expanded
at 37 °C in skeletal muscle growth medium (PromoCell,
Heidelberg, Germany) supplemented with 10 % FCS
(Gibco, Paisely, UK). The cultures were enriched in
myoblasts by immuno-magnetic cell sorting using anti-
CD56/NCAM antibody coated magnetic beads (Miltenyi
Biotech, Bergisch Gladbach, Germany). Purity of the
myoblast preparation was verified by staining with an
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desmin-positive cells.
Immortalization of primary human myoblasts and their
differentiation into myotubes
Primary human dysferlin-deficient myoblast lines were
transduced with pBABE retroviral vectors carrying
Cdk4 and hTERT. Puromycin and neomycin were
used as selection markers, respectively and isolation
of individual myogenic clones was carried out as de-
scribed by Mamchaoui et al. [31]. The immortalized
dysferlin-deficient human myoblast lines were cul-
tured in growth medium consisting of 1 vol 199
Medium (Invitrogen, Carlsbad, CA)/4 vol DMEM
(Invitrogen) supplemented with 20 % foetal calf serum
(Invitrogen), 2.5 ng/ml HGF (Invitrogen), 0.1 μM
Dexamethasone (Sigma-Aldrich, St. Louis, MO) and
50 μg/ml Gentamycin (Invitrogen). Differentiation into
myotubes was initiated at approximately 90 % confluence
by cultivation in differentiation medium (DMEM/F12, 5 %
horse serum, insulin 10 μg/ml) for 14 days.
Four different dysferlin-mutated myoblast lines were
generated and called 107, 379, AB320 and ER, each one
bearing a different dysferlin mutation as follow: 107,
c.855 + 1delG c.895G > A; 379, c.1448C > A c.107 T > A;
AB320, c.342-1G >A HTZ c.3516_3517delTT (p.Ser1173X)
HTZ; ER, G1628R(c.4882G > A)HMZ.
Intracellular Ca2+ Signals
Basal intracellular Ca2+ signals were evaluated in
myotubes by using the ratiometric dye FURA 2-AM.
The myotubes were incubated in Krebs-Ringer buffer
(in mM: 145 NaCl, 5 KCl, 3 CaCl2, 1 MgCl2, 5.6 glu-
cose, 10 HEPES-Na, pH7.4) containing FURA2-AM
dye (2 μM) during 55 min at room temperature.
Then, the Ca2+ signal was evaluated in a Nikon Eclipse Ti
microscope equipped with epifluorescence illumination,
and images were obtained by using a Clara camera
(Andor), at 2 wavelength (λ) 340 and 380 nm, calculating
the ratio 340 vs 380.
Membrane permeability to dyes
The uptake of ethidium (Etd+) was evaluated by
using time lapse measurements. Human myotubes
plated onto glass cover slips were washed twice with
Krebs-buffer solution. For time lapse measurements
myotubes were incubated in Krebs buffer solution
containing 5 μM Etd+ bromide. Etd+ fluorescence
was recorded in regions of interest located in nuclei
of the myofibers. An epifluorescence Nikon Ti
microscope was used. Images were captured with a
Clara camera (Andor) every 30 s. Image processing
was performed off-line with ImageJ software (NIH,
Bethesda, USA).Immunofluorescence analysis
To detect different proteins in myotubes or cross
sections (10 μm) of muscles (fast frozen with iso-
methyl-butane cooled in liquid nitrogen) samples
were obtained and processed as described previously
[11]. Briefly, samples were fixed in paraformaldehyde
4 % by 5 min, then incubated at 4 °C for 12 h with
diluted primary anti-Cx40.1 (1:100), anti-Cx43 (1:250),
anti-Cx45 (1:250), anti-Panx1 (1:300), anti-TRPV2
(1:100) or anti-P2X7 (1:100) antibodies followed by 4
washes with PBS 1X and then, incubated with an ap-
propriate dilution of alexa488-conjugated goat anti-
rabbit or anti-mouse IgG antibodies. Samples were
rinsed with PBS 1X, mounted with fluoromount G
containing DAPI on glass slides and representative
images were acquired in an epifluorescence micro-
scope Nikon Ti (Tokio, Japan).
Silencing of dysferlin by small hairpin RNA
Commercial small hairpin RNA plasmid against dys-
ferlin (Santa Cruz Biotech, Dallas, Tx), with puro-
mycin resistance, was used to transfect RCMH
myoblast through lypofectamine method [32]. The si-
lencing of dysferlin was confirmed by western blot
analysis.
Selection of dysferlinopathy patients, mutations and
biopsy studies
Following ethical guidelines, healthy volunteers and dys-
ferlinopathy patients who participated in this study signed
an informed consent approved by the local Ethics
Committee in accordance with the ethical standards
laid down in the 1964 Declaration of Helsinki and its
later amendments. Diagnosis of dysferlinopathy was
achieved based on clinical examination, muscular bi-
opsy and mutation analysis. The mutations of the pa-
tients are published in Woudt et al. [33].
Statistical analysis
Results are presented as mean ± standard error (SE). For
multiple comparisons with a single control, a non-
parametric one-way ANOVA followed by the Dunn’s
multiple comparison test was used. Analyses were
carried out using GRAPHPAD software. P < 0.05 was
considered statistically significant.
Additional file
Additional file 1: Figure S1. TRPV2 channels are functionally expressed
in absence of dysferlin. Human control myotubes, RCMH myotubes (◯);
human myotubes that lack dysferlin, small hairpin RNA Dysferlin (□); and
myotubes 379 (∇), were loaded with Fura-2 AM dye and the Ca2+ elevation,
induced by 2-Aminoethoxydiphenyl borate (2-APB), was evaluated
and compared with that of RCMH myotubes that express dysferlin. The data
represents mean ± SEM. n = 4 cell cultures for each cell line. (JPG 371 kb)
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